- Home
- NERV vs BGLC Comparison
NERV vs BGLC Comparison
Compare NERV & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- BGLC
- Stock Information
- Founded
- NERV 2007
- BGLC 2017
- Country
- NERV United States
- BGLC Malaysia
- Employees
- NERV N/A
- BGLC N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- BGLC Medical Specialities
- Sector
- NERV Health Care
- BGLC Health Care
- Exchange
- NERV Nasdaq
- BGLC Nasdaq
- Market Cap
- NERV 12.0M
- BGLC 10.7M
- IPO Year
- NERV 2014
- BGLC N/A
- Fundamental
- Price
- NERV $2.25
- BGLC $5.34
- Analyst Decision
- NERV Hold
- BGLC
- Analyst Count
- NERV 1
- BGLC 0
- Target Price
- NERV $5.00
- BGLC N/A
- AVG Volume (30 Days)
- NERV 35.1K
- BGLC 3.1M
- Earning Date
- NERV 08-14-2025
- BGLC 08-26-2025
- Dividend Yield
- NERV N/A
- BGLC N/A
- EPS Growth
- NERV N/A
- BGLC N/A
- EPS
- NERV 1.48
- BGLC N/A
- Revenue
- NERV N/A
- BGLC $9,265,870.00
- Revenue This Year
- NERV N/A
- BGLC N/A
- Revenue Next Year
- NERV N/A
- BGLC N/A
- P/E Ratio
- NERV $1.52
- BGLC N/A
- Revenue Growth
- NERV N/A
- BGLC N/A
- 52 Week Low
- NERV $1.15
- BGLC $2.01
- 52 Week High
- NERV $3.00
- BGLC $15.60
- Technical
- Relative Strength Index (RSI)
- NERV 69.92
- BGLC 49.57
- Support Level
- NERV $1.79
- BGLC $5.28
- Resistance Level
- NERV $1.81
- BGLC $5.85
- Average True Range (ATR)
- NERV 0.10
- BGLC 0.71
- MACD
- NERV 0.01
- BGLC -0.12
- Stochastic Oscillator
- NERV 76.56
- BGLC 20.52
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.